The estimated Net Worth of Anup Marda is at least $1.74 Milion dollars as of 18 October 2022. Mr. Marda owns over 50,000 units of Cabaletta Bio Inc stock worth over $213,000 and over the last 5 years he sold CABA stock worth over $0. In addition, he makes $1,528,630 as Chief Financial Officer at Cabaletta Bio Inc.
Anup has made over 1 trades of the Cabaletta Bio Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of CABA stock worth $49,500 on 18 October 2022.
The largest trade he's ever made was buying 50,000 units of Cabaletta Bio Inc stock on 18 October 2022 worth over $49,500. On average, Anup trades about 7,143 units every 0 days since 2019. As of 18 October 2022 he still owns at least 50,000 units of Cabaletta Bio Inc stock.
You can see the complete history of Mr. Marda stock trades at the bottom of the page.
Anup Marda serves as Chief Financial Officer of the Company. From April 2001 to January 2019, Mr. Marda held positions at Bristol-Myers Squibb, including, most recently, as Vice President, Head of Global Corporate Financial Planning & Analysis, and previously as Head of Finance, R&D Operations and Head of Finance, R&D Portfolio Management and Global Medical from 2014 to 2018. Prior to this, Mr. Marda held the role of Executive Director, U.S. Pharmaceuticals from 2012 to 2014 and Assistant Treasurer, Capital Markets from 2008 to 2012. Mr. Marda received his MBA from the Krannert School of Business of Purdue University and his B.Tech in Chemical Engineering from the Indian Institute of Technology Bombay.
As the Chief Financial Officer of Cabaletta Bio Inc, the total compensation of Anup Marda at Cabaletta Bio Inc is $1,528,630. There are no executives at Cabaletta Bio Inc getting paid more.
Anup Marda is 42, he's been the Chief Financial Officer of Cabaletta Bio Inc since 2019. There are 13 older and 1 younger executives at Cabaletta Bio Inc. The oldest executive at Cabaletta Bio Inc is Richard Henriques, 64, who is the Independent Director.
Anup's mailing address filed with the SEC is C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA, PA, 19104.
Over the last 5 years, insiders at Cabaletta Bio Inc have traded over $19,324,000 worth of Cabaletta Bio Inc stock and bought 1,500,545 units worth $13,043,398 . The most active insiders traders include Group, Llc Green Jeremy Red..., Ventures V, L.P.5 Am Opport... a James E Deerfield Mgmt Iv, .... On average, Cabaletta Bio Inc executives and independent directors trade stock every 70 days with the average trade being worth of $632,329. The most recent stock trade was executed by Gwendolyn Binder on 19 January 2024, trading 11,000 units of CABA stock currently worth $11,110.
cabaletta bio, inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered t cell therapies for patients with b cell-mediated autoimmune diseases. its proprietary technology utilizes chimeric autoantibody receptor (caar) t cells that are designed to selectively bind and eliminate b cells, which produce disease-causing autoantibodies or pathogenic b cells. the company's lead product candidate is dsg3-caart, which is in phase i clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and hemophilia a with factor viii alloantibodies. its product candidate pipeline also include musk-caart, a preclinical stage product to treat a subset of patients with myasthenia gravis; fviii-caart, a discovery stage product to treat a subset of patients with hemophilia a; and dsg3/1-caart, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. cabaletta bio, inc. has a collaboration with the un
Cabaletta Bio Inc executives and other stock owners filed with the SEC include: